<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Direct oral anticoagulant-associated bleeding reversal strategies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Direct oral anticoagulant-associated bleeding reversal strategies</h1>
<div class="graphic"><div class="figure"><div class="ttl">Direct oral anticoagulant-associated bleeding reversal strategies</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="50%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Type of bleeding</td> <td class="subtitle1">Agent</td> <td class="subtitle1">Possible interventions</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="2">Life-threatening or imminently fatal bleeding (eg, intracranial, retroperitoneal, compartment syndrome, massive gastrointestinal)</td> <td>Dabigatran (Pradaxa)</td> <td> <ul> <li>Idarucizumab</li> <li>Activated PCC* (eg, FEIBA)</li> <li>Antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid)</li> <li>Anticoagulant discontinuation</li> <li>Oral activated charcoal (if last dose within prior two hours)</li> <li>Hemodialysis</li> <li>RBC transfusions if needed for anemia</li> <li>Platelet transfusions if needed for thrombocytopenia or impaired platelet function (eg, due to aspirin)</li> <li>Surgical/endoscopic intervention if appropriate</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana)</td> <td> <ul> <li>Andexanet alfa (AndexXa) <strong>or</strong> a 4-factor unactivated PCC (eg, Kcentra)</li> <li>Antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid)</li> <li>Anticoagulant discontinuation</li> <li>Oral activated charcoal (if last dose recent enough)</li> <li>RBC transfusions if needed for anemia</li> <li>Platelet transfusions if needed for thrombocytopenia or impaired platelet function (eg, due to aspirin)</li> <li>Surgical/endoscopic intervention if appropriate</li> </ul> </td> </tr> <tr> <td rowspan="2">Minor bleeding (eg, epistaxis, uncomplicated soft tissue bleeding, minor [slow] gastrointestinal bleeding)</td> <td>Dabigatran (Pradaxa)</td> <td> <ul> <li>Local hemostatic measures</li> <li>Possible anticoagulant discontinuation <ul> <li>Half-life (normal renal function<sup>¶</sup>): 12 to 17 hours</li> </ul> </li> <li>Possible antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid)</li> </ul> </td> </tr> <tr> <td>Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana)</td> <td> <ul> <li>Local hemostatic measures</li> <li>Possible anticoagulant discontinuation <ul> <li>Half-lives (normal renal function<sup>¶</sup>): <ul> <li>Rivaroxaban 5 to 9 hours</li> <li>Apixaban 8 to 15 hours</li> <li>Edoxaban 6 to 11 hours</li> </ul> </li> </ul> </li> <li>Possible antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The table describes measures that may be used to manage bleeding associated with DOACs. Clinical judgment is essential in all cases of DOAC-associated bleeding in order to assess the risks of bleeding and weigh these against the risks of thrombosis if anticoagulation is discontinued or reversed. Refer to UpToDate topics on the use of direct thrombin inhibitors and direct factor Xa inhibitors and management of DOAC-associated bleeding for further details and dosing. The onset of all of the agents discussed herein is approximately 2 to 4 hours.</div><div class="graphic_footnotes">PCC: prothrombin complex concentrate; FEIBA: factor eight inhibitor bypassing activity; RBC: red blood cell; DOAC: direct oral anticoagulant.<br/>
* Use activated PCC only if idarucizumab is unavailable and/or if continued bleeding is reasonably likely to be fatal within hours.<br/>
¶ The anticoagulant effect of these agents (especially dabigatran) will dissipate more slowly as renal function declines. Severe hepatic failure may also prolong the half-life for apixaban, edoxaban, and rivaroxaban.</div><div id="graphicVersion">Graphic 96230 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
